Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Presents Primate Data on Subcutaneous Cholesterol Drug

Premium

Alnylam Pharmaceuticals this week released new preclinical data showing that its subcutaneously delivered hypercholesterolemia drug ALN-PCSsc could knock its target down by as much as 95 percent and decrease low-density lipoprotein levels by up to 67 percent in non-human primates.

ALN-PCSsc is preclinical a version of Alnylam's phase II intravenously delivered drug ALN-PCS, which targets proprotein convertase subtilisin/kexin type 9. Earlier this year, The Medicines Company acquired the rights to develop and commercialize both agents after phase II testing.

"Our new study results in non-human primates show an up to 95 percent knockdown of plasma PCSK9 and an up to 67 percent reduction of LDL-C in the absence of statin co-administration, with a very durable knockdown of more than 50 days after the last dose," Alnylam's Vice President of Research Rachel Meyers said in a statement. "We believe these results support a highly competitive target product profile, and we look forward to advancing ALN-PCSsc toward clinical trials in 2014 with our partner The Medicines Company."

The data were presented at this year's American Heart Association Scientific Sessions.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.